{"id":2610,"date":"2026-04-21T10:00:00","date_gmt":"2026-04-21T14:00:00","guid":{"rendered":"https:\/\/glycovax.com\/?p=2610"},"modified":"2026-04-22T08:12:48","modified_gmt":"2026-04-22T12:12:48","slug":"glycovax-universite-laval-licence-galectine-3-nouvelle","status":"publish","type":"post","link":"https:\/\/glycovax.com\/fr\/glycovax-universite-laval-licence-galectine-3-nouvelle\/","title":{"rendered":"Glycovax Pharma et l\u2019Universit\u00e9 Laval d\u00e9veloppent des inhibiteurs innovants ciblant la galectine-3"},"content":{"rendered":"\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<img decoding=\"async\" src=\"https:\/\/glycovax.com\/wp-content\/uploads\/2024\/12\/Glycovax-Pharma-horizontal-couleur.svg\" alt=\"Glycovax Pharma\" style=\"width:200px; height:auto; display:block; margin:0 auto;\">\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<img decoding=\"async\" src=\"https:\/\/glycovax.com\/wp-content\/uploads\/2026\/04\/Universite_Laval_logo_et_texte-1024x445.png\" alt=\"Universit\u00e9 Laval\" style=\"width:200px; height:auto; display:block; margin:0 auto;\">\n<\/div>\n<\/div>\n\n\n\n<p>La FPI (fibrose pulmonaire idiopathique) affecte environ 15\u2009000&nbsp;personnes au Canada, 100\u2009000 aux \u00c9tats-Unis et 200\u2009000 en Europe tandis que la NASH (st\u00e9atoh\u00e9patite non alcoolique) affecte environ 38&nbsp;millions d\u2019Am\u00e9ricains, 10&nbsp;millions d\u2019Europ\u00e9ens et 1,5&nbsp;million de Canadiens.<\/p>\n\n\n\n<p>Le professeur Denis Gigu\u00e8re, du D\u00e9partement de chimie de l\u2019Universit\u00e9 Laval, un expert en chimie des glucides et en conception de mol\u00e9cules complexes, a d\u00e9velopp\u00e9 une technologie de rupture pour combler certaines limites pharmacologiques et am\u00e9liorer la s\u00e9lectivit\u00e9 de la galectine-3. Gr\u00e2ce au savoir-faire de Glycovax et \u00e0 sa licence mondiale exclusive, le programme entre maintenant dans une phase d\u2019acc\u00e9l\u00e9ration qui vise \u00e0 progresser vers l\u2019identification d\u2019applications th\u00e9rapeutiques concr\u00e8tes \u00e0 fort potentiel clinique.<\/p>\n\n\n\n<p><a href=\"https:\/\/glycovax.com\/wp-content\/uploads\/2026\/04\/COMM-ULaval-Glycovax-22-04-26-vf3.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Lire la suite&#8230;<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>La FPI (fibrose pulmonaire idiopathique) affecte environ 15\u2009000&nbsp;personnes au Canada, 100\u2009000 aux \u00c9tats-Unis et 200\u2009000 en Europe tandis que la NASH (st\u00e9atoh\u00e9patite non alcoolique) affecte environ 38&nbsp;millions d\u2019Am\u00e9ricains, 10&nbsp;millions d\u2019Europ\u00e9ens et 1,5&nbsp;million de Canadiens. Le professeur Denis Gigu\u00e8re, du D\u00e9partement de chimie de l\u2019Universit\u00e9 Laval, un expert en chimie des glucides et en conception de&hellip;<\/p>\n","protected":false},"author":2,"featured_media":2606,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[95],"tags":[94],"class_list":["post-2610","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-nouvelles","tag-featured-fr"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Glycovax et l&#039;Universit\u00e9 Laval : inhibiteurs galectine-3<\/title>\n<meta name=\"description\" content=\"Glycovax Pharma et l&#039;Universit\u00e9 Laval d\u00e9veloppent des inhibiteurs innovants de la galectine-3 pour traiter la FPI, la NASH et d&#039;autres maladies fibrotiques graves.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/glycovax.com\/fr\/glycovax-universite-laval-licence-galectine-3-nouvelle\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Glycovax et l&#039;Universit\u00e9 Laval : inhibiteurs galectine-3\" \/>\n<meta property=\"og:description\" content=\"Glycovax Pharma et l&#039;Universit\u00e9 Laval d\u00e9veloppent des inhibiteurs innovants de la galectine-3 pour traiter la FPI, la NASH et d&#039;autres maladies fibrotiques graves.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/glycovax.com\/fr\/glycovax-universite-laval-licence-galectine-3-nouvelle\/\" \/>\n<meta property=\"og:site_name\" content=\"Glycovax Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-21T14:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-22T12:12:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/glycovax.com\/wp-content\/uploads\/2026\/04\/Glycovax-Laval-facebook-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Claude Dagenais\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Claude Dagenais\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-universite-laval-licence-galectine-3-nouvelle\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-universite-laval-licence-galectine-3-nouvelle\\\/\"},\"author\":{\"name\":\"Claude Dagenais\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#\\\/schema\\\/person\\\/791c61a78825c9dc04135e2ceaca3883\"},\"headline\":\"Glycovax Pharma et l\u2019Universit\u00e9 Laval d\u00e9veloppent des inhibiteurs innovants ciblant la galectine-3\",\"datePublished\":\"2026-04-21T14:00:00+00:00\",\"dateModified\":\"2026-04-22T12:12:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-universite-laval-licence-galectine-3-nouvelle\\\/\"},\"wordCount\":144,\"publisher\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-universite-laval-licence-galectine-3-nouvelle\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/glycovax.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Glycovax-Laval-facebook-1.jpg\",\"keywords\":[\"Featured\"],\"articleSection\":[\"Nouvelles\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-universite-laval-licence-galectine-3-nouvelle\\\/\",\"url\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-universite-laval-licence-galectine-3-nouvelle\\\/\",\"name\":\"Glycovax et l'Universit\u00e9 Laval : inhibiteurs galectine-3\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-universite-laval-licence-galectine-3-nouvelle\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-universite-laval-licence-galectine-3-nouvelle\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/glycovax.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Glycovax-Laval-facebook-1.jpg\",\"datePublished\":\"2026-04-21T14:00:00+00:00\",\"dateModified\":\"2026-04-22T12:12:48+00:00\",\"description\":\"Glycovax Pharma et l'Universit\u00e9 Laval d\u00e9veloppent des inhibiteurs innovants de la galectine-3 pour traiter la FPI, la NASH et d'autres maladies fibrotiques graves.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-universite-laval-licence-galectine-3-nouvelle\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-universite-laval-licence-galectine-3-nouvelle\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-universite-laval-licence-galectine-3-nouvelle\\\/#primaryimage\",\"url\":\"https:\\\/\\\/glycovax.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Glycovax-Laval-facebook-1.jpg\",\"contentUrl\":\"https:\\\/\\\/glycovax.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Glycovax-Laval-facebook-1.jpg\",\"width\":1200,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/glycovax-universite-laval-licence-galectine-3-nouvelle\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Glycovax Pharma et l\u2019Universit\u00e9 Laval d\u00e9veloppent des inhibiteurs innovants ciblant la galectine-3\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/\",\"name\":\"Glycovax Pharma\",\"description\":\"Saving millions of lives by using the power of advanced medical nanotechnology.\",\"publisher\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#organization\"},\"alternateName\":\"Glycovax\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#organization\",\"name\":\"Glycovax Pharma\",\"alternateName\":\"Glycovax\",\"url\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/glycovax.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/Glycovax-Pharma-carre.png\",\"contentUrl\":\"https:\\\/\\\/glycovax.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/Glycovax-Pharma-carre.png\",\"width\":1200,\"height\":1200,\"caption\":\"Glycovax Pharma\"},\"image\":{\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/glycovax.com\\\/fr\\\/#\\\/schema\\\/person\\\/791c61a78825c9dc04135e2ceaca3883\",\"name\":\"Claude Dagenais\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f4b8cea30a420f348ecee86e20e8aa60d5506584eaad9180873c59b61f2260fe?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f4b8cea30a420f348ecee86e20e8aa60d5506584eaad9180873c59b61f2260fe?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f4b8cea30a420f348ecee86e20e8aa60d5506584eaad9180873c59b61f2260fe?s=96&d=mm&r=g\",\"caption\":\"Claude Dagenais\"},\"sameAs\":[\"https:\\\/\\\/twohumans.com\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Glycovax et l'Universit\u00e9 Laval : inhibiteurs galectine-3","description":"Glycovax Pharma et l'Universit\u00e9 Laval d\u00e9veloppent des inhibiteurs innovants de la galectine-3 pour traiter la FPI, la NASH et d'autres maladies fibrotiques graves.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/glycovax.com\/fr\/glycovax-universite-laval-licence-galectine-3-nouvelle\/","og_locale":"fr_FR","og_type":"article","og_title":"Glycovax et l'Universit\u00e9 Laval : inhibiteurs galectine-3","og_description":"Glycovax Pharma et l'Universit\u00e9 Laval d\u00e9veloppent des inhibiteurs innovants de la galectine-3 pour traiter la FPI, la NASH et d'autres maladies fibrotiques graves.","og_url":"https:\/\/glycovax.com\/fr\/glycovax-universite-laval-licence-galectine-3-nouvelle\/","og_site_name":"Glycovax Pharma","article_published_time":"2026-04-21T14:00:00+00:00","article_modified_time":"2026-04-22T12:12:48+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/glycovax.com\/wp-content\/uploads\/2026\/04\/Glycovax-Laval-facebook-1.jpg","type":"image\/jpeg"}],"author":"Claude Dagenais","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Claude Dagenais","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/glycovax.com\/fr\/glycovax-universite-laval-licence-galectine-3-nouvelle\/#article","isPartOf":{"@id":"https:\/\/glycovax.com\/fr\/glycovax-universite-laval-licence-galectine-3-nouvelle\/"},"author":{"name":"Claude Dagenais","@id":"https:\/\/glycovax.com\/fr\/#\/schema\/person\/791c61a78825c9dc04135e2ceaca3883"},"headline":"Glycovax Pharma et l\u2019Universit\u00e9 Laval d\u00e9veloppent des inhibiteurs innovants ciblant la galectine-3","datePublished":"2026-04-21T14:00:00+00:00","dateModified":"2026-04-22T12:12:48+00:00","mainEntityOfPage":{"@id":"https:\/\/glycovax.com\/fr\/glycovax-universite-laval-licence-galectine-3-nouvelle\/"},"wordCount":144,"publisher":{"@id":"https:\/\/glycovax.com\/fr\/#organization"},"image":{"@id":"https:\/\/glycovax.com\/fr\/glycovax-universite-laval-licence-galectine-3-nouvelle\/#primaryimage"},"thumbnailUrl":"https:\/\/glycovax.com\/wp-content\/uploads\/2026\/04\/Glycovax-Laval-facebook-1.jpg","keywords":["Featured"],"articleSection":["Nouvelles"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/glycovax.com\/fr\/glycovax-universite-laval-licence-galectine-3-nouvelle\/","url":"https:\/\/glycovax.com\/fr\/glycovax-universite-laval-licence-galectine-3-nouvelle\/","name":"Glycovax et l'Universit\u00e9 Laval : inhibiteurs galectine-3","isPartOf":{"@id":"https:\/\/glycovax.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/glycovax.com\/fr\/glycovax-universite-laval-licence-galectine-3-nouvelle\/#primaryimage"},"image":{"@id":"https:\/\/glycovax.com\/fr\/glycovax-universite-laval-licence-galectine-3-nouvelle\/#primaryimage"},"thumbnailUrl":"https:\/\/glycovax.com\/wp-content\/uploads\/2026\/04\/Glycovax-Laval-facebook-1.jpg","datePublished":"2026-04-21T14:00:00+00:00","dateModified":"2026-04-22T12:12:48+00:00","description":"Glycovax Pharma et l'Universit\u00e9 Laval d\u00e9veloppent des inhibiteurs innovants de la galectine-3 pour traiter la FPI, la NASH et d'autres maladies fibrotiques graves.","breadcrumb":{"@id":"https:\/\/glycovax.com\/fr\/glycovax-universite-laval-licence-galectine-3-nouvelle\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/glycovax.com\/fr\/glycovax-universite-laval-licence-galectine-3-nouvelle\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/glycovax.com\/fr\/glycovax-universite-laval-licence-galectine-3-nouvelle\/#primaryimage","url":"https:\/\/glycovax.com\/wp-content\/uploads\/2026\/04\/Glycovax-Laval-facebook-1.jpg","contentUrl":"https:\/\/glycovax.com\/wp-content\/uploads\/2026\/04\/Glycovax-Laval-facebook-1.jpg","width":1200,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/glycovax.com\/fr\/glycovax-universite-laval-licence-galectine-3-nouvelle\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/glycovax.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Glycovax Pharma et l\u2019Universit\u00e9 Laval d\u00e9veloppent des inhibiteurs innovants ciblant la galectine-3"}]},{"@type":"WebSite","@id":"https:\/\/glycovax.com\/fr\/#website","url":"https:\/\/glycovax.com\/fr\/","name":"Glycovax Pharma","description":"Saving millions of lives by using the power of advanced medical nanotechnology.","publisher":{"@id":"https:\/\/glycovax.com\/fr\/#organization"},"alternateName":"Glycovax","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/glycovax.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/glycovax.com\/fr\/#organization","name":"Glycovax Pharma","alternateName":"Glycovax","url":"https:\/\/glycovax.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/glycovax.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/glycovax.com\/wp-content\/uploads\/2025\/04\/Glycovax-Pharma-carre.png","contentUrl":"https:\/\/glycovax.com\/wp-content\/uploads\/2025\/04\/Glycovax-Pharma-carre.png","width":1200,"height":1200,"caption":"Glycovax Pharma"},"image":{"@id":"https:\/\/glycovax.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/glycovax.com\/fr\/#\/schema\/person\/791c61a78825c9dc04135e2ceaca3883","name":"Claude Dagenais","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/f4b8cea30a420f348ecee86e20e8aa60d5506584eaad9180873c59b61f2260fe?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/f4b8cea30a420f348ecee86e20e8aa60d5506584eaad9180873c59b61f2260fe?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f4b8cea30a420f348ecee86e20e8aa60d5506584eaad9180873c59b61f2260fe?s=96&d=mm&r=g","caption":"Claude Dagenais"},"sameAs":["https:\/\/twohumans.com\/"]}]}},"_links":{"self":[{"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/posts\/2610","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/comments?post=2610"}],"version-history":[{"count":2,"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/posts\/2610\/revisions"}],"predecessor-version":[{"id":2623,"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/posts\/2610\/revisions\/2623"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/media\/2606"}],"wp:attachment":[{"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/media?parent=2610"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/categories?post=2610"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/glycovax.com\/fr\/wp-json\/wp\/v2\/tags?post=2610"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}